🔎 Trials Near Me

Hjem › Akut myelogen leukemi › California › San Francisco

Kliniske studier for Akut myelogen leukemi i San Francisco, CA

12 studier for Akut myelogen leukemi søker deltakere på steder i og rundt San Francisco (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Kaiser Permanente-San Francisco, San Francisco
  • UCSF Medical Center-Parnassus, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • UCSF Medical Center-Parnassus, San Francisco
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • UCSF Medical Center-Parnassus, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • UCSF Medical Center-Parnassus, San Francisco
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Kaiser Permanente-San Francisco, San Francisco
  • UCSF Medical Center-Parnassus, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • UCSF Medical Center-Mission Bay, San Francisco
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

RekruttererFase 3
  • US-San Francisco CA-UCSF, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • US-San Francisco CA-UCSF, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 1. sep. 2026 · NCT07223814

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • Benioff Children's Hospital - Mission Bay, San Francisco
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • University of California San Francisco, San Francisco
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • UCSF (Peds), San Francisco
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

Akut myelogen leukemi-studier i andre byer

Andre studier i San Francisco

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.